Cisplatin IV
DrugCisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
NCT Number: NCT01029678
The purpose of this study is to evaluate the safety of non small cell lung cancer (NSCLC) treatment with cisplatin and oral vinorelbine administered weekly associated with concomitant radiotherapy in elderly patients.
Looking for future studies?
Notify Me70 year and older
All sexes
Interventional
Phase 2
CHU Brest, Brest, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
The disease
Exclusion criteria
The disease
Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
66Gy, 33 fractions, 6 week
Time frame: during treatment and during the 4 weeks following the end of treatment
Time frame: 6 months after the end of the treatment
Time frame: 4 weeks after treatment
University Hospital, Limoges
Other
Phase II Study Evaluating Treatment With Oral Navelbine and Cisplatin Administered Weekly and Concomitant Radiotherapy in Elderly Patients With no Operable NSCLC
Acronym: RACCOSA
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05375994
Advanced Cancer, Bronchial Neoplasms
San Francisco, California, United States
View Trial DetailsNCT04939324
Bronchial Neoplasms, Carcinoma, Bronchogenic
Limoges, France
View Trial DetailsNCT00818558
Bronchial Neoplasms, Carcinoma, Bronchogenic
Nice, France
View Trial DetailsNCT06196424
Bronchial Neoplasms, Carcinoma, Bronchogenic
Milan, Italy
View Trial Details